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Abstract: Carbon monoxide (CO)-releasing molecules (CORMs) are used to deliver CO, a biological
‘gasotransmitter’, in biological chemistry and biomedicine. CORMs kill bacteria in culture and in ani-
mal models, but are reportedly benign towards mammalian cells. CORM-2 (tricarbonyldichlororuthe-
nium(II) dimer, Ru2Cl4(CO)6), the first widely used and commercially available CORM, displays
numerous pharmacological, biochemical and microbiological activities, generally attributed to CO
release. Here, we investigate the basis of its potent antibacterial activity against Escherichia coli
and demonstrate, using three globin CO sensors, that CORM-2 releases negligible CO (<0.1 mol
CO per mol CORM-2). A strong negative correlation between viability and cellular ruthenium
accumulation implies that ruthenium toxicity underlies biocidal activity. Exogenous amino acids and
thiols (especially cysteine, glutathione and N-acetyl cysteine) protected bacteria against inhibition
of growth by CORM-2. Bacteria treated with 30 µM CORM-2, with added cysteine and histidine,
exhibited no significant loss of viability, but were killed in the absence of these amino acids. Their pre-
vention of toxicity correlates with their CORM-2-binding affinities (Cys, Kd 3 µM; His, Kd 130 µM) as
determined by 1H-NMR. Glutathione is proposed to be an important intracellular target of CORM-2,
with CORM-2 having a much higher affinity for reduced glutathione (GSH) than oxidised glutathione
(GSSG) (GSH, Kd 2 µM; GSSG, Kd 25,000 µM). The toxicity of low, but potent, levels (15 µM) of
CORM-2 was accompanied by cell lysis, as judged by the release of cytoplasmic ATP pools. The
biological effects of CORM-2 and related CORMs, and the design of biological experiments, must be
re-examined in the light of these data.
Keywords: amino acid; antimicrobial agent; bacteria; carbon monoxide; CORM-2; glutathione; metal;
ruthenium compound; thiol
1. Introduction
Carbon monoxide (CO) has been a valuable tool in biological chemistry since the 1890s
when Hoppe-Seyler demonstrated the absorbance spectrum of CO-haemoglobin in pigeon
heart muscle. CO continues to be used as a haem ligand [1] and is treated with respect in the
laboratory owing to its well-known toxicity. Nevertheless, CO is produced endogenously
in biology by haem oxygenases (HO) and its biological functions are actively studied [2].
The gas is now recognised as a potent biological messenger in mammalian systems and
is involved in diverse signalling processes, including the production of inflammatory
mediators [3], cell survival and apoptosis [4], signalling in the central nervous system [5]
and in bacterial infection [6].
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Over the past decade, many novel transition metal-based carbon monoxide-releasing
molecules (CORMs) have been developed to mimic haem oxygenase activity and de-
liver physiologically relevant levels of CO experimentally or therapeutically [7,8]. The
widespread use of these compounds as CO donors has accelerated our understanding of
CO as an important gasotransmitter molecule in human and animal biology [9]. Increas-
ingly, CORMs are considered as potential pro-drugs for CO delivery, not only in clinical and
physiological applications [10,11], but also as anticancer drugs [12] and antimicrobials [13].
Recently, hybrid CORMs have been developed in which, for example, a cobalt–carbonyl as
a CO releaser is complexed with a fumaric acid derivative as an Nrf2/HO-1 activator [14].
Thus, CORM biology is a highly active area of research.
The earliest report that CORMs liberate CO describes CORM-2 (Ru2Cl4(CO)6, tri-
carbonyldichlororuthenium(II) dimer) [15], which is readily available commercially at
low cost. More than 400 papers now describe its activities and uses. Spectrophotometric
and NMR analysis revealed that it releases CO in a concentration-dependent manner
and caused sustained vasodilation in pre-contracted rat aortic rings, attenuated coronary
vasoconstriction in hearts ex vivo and significantly reduced acute hypertension in vivo.
These vascular effects were mimicked by induction of HO-1 after treatment of animals
with haemin, which increases endogenously generated CO [15]. Injection of CORM-2 into
mice increased phagocytosis of bacteria and rescued haem oxygenase-deficient mice from
sepsis-induced lethality [16]. In the light of the above controls and the use of haemoglobin
in bacterial cultures to scavenge released CO [17], it has been tacitly assumed that all exper-
imental effects of CORM-2 (and other CORMs) are due to the released CO. For example, a
recent study demonstrated the significant enhancement by CORM-2 of clot formation and
strength in the plasma of dogs, and this was attributed to the released CO [18]. Gastric ulcer
healing in rats was also accelerated by CORM-2 modulated by increased gastric mucosal
content of CO released from its pharmacological donor; CO content in gastric mucosa was
elevated after CORM-2 administration [19]. In some studies, however, CO gas and CORM-
2 are erroneously assumed to be equivalent: for example, Zacharia et al. [20] isolated
CO-resistant mutants of Mycobacterium tuberculosis, in a gene named cor (CO resistance),
after growth of a transposon library in the presence of 2% CO gas, but the susceptibility to
CO of E. coli cells expressing the cor gene was evaluated with CORM-2.
Despite its widespread use, CORM-2 has the serious disadvantage of being insol-
uble in water, aqueous media and many organic solvents. For biological use, CORM-2
is dissolved in dimethylsulfoxide (DMSO) where it undergoes [21,22] a transition into
mononuclear Ru(II)–carbonyl complexes by displacement of the chloride bridges with
DMSO [21,23,24], but there are additional complex changes that are incompletely under-
stood. These monomers may react further with DMSO, via displacement of one CO ligand
by coordination of the sulphur atom of DMSO to the Ru(II) ion, yielding [RuCl2(CO)2-
(DMSO)2] isomers, which are relatively stable. As a consequence of this chemistry, CORM-2
solutions in DMSO probably represent a mixture of the forms in Figure 1, depending on
the age of the solution [21,22]. Such heterogeneous mixtures may undergo further chemical
changes and ligand exchange. The availability of CO is of paramount importance. Des-
mard [25] classified CORM-2 as a ‘fast CO releaser’, based on its ability to rapidly convert
ferrous myoglobin to carbonmonoxy myoglobin in the presence of dithionite. However,
little or no CO was detected on addition of, presumably heterogeneous, stock solutions
of CORM-2 to buffers or media when assayed via the alternative oxyhaemoglobin assay
(which avoids dithionite [26]), or by a CO electrode, gas-phase Fourier transform infrared
spectroscopy or gas chromatography [17,21,22,25].
We recently proposed a radically different explanation for the toxic biological activities
of a related Ru–carbonyl CORM, namely CORM-3, [Ru(CO)3Cl(glycinate)], and argued
that, rather than acting as an antimicrobial agent via release of CO, CORM-3 is a source
of Ru(II), which reacts with cellular targets [27]. Indeed, over 200 publications report the
antimicrobial activities of various Ru-based compounds that are not CORMs; in some,
the Ru ions play a direct functional role, directly coordinating to biological targets [24].
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These findings have far-reaching implications for understanding the toxicity of these agents
against both microbial and mammalian cells and for their possible development as useful
pharmaceuticals.
μ
Figure 1. Structure of CORM-2 (1) prior to dissolution in dimethyl sulfoxide (DMSO). After addition of DMSO, the chloride
bridges of the CORM-2 dimer are displaced by attack of DMSO to the Ru(II) ion(s) yielding two identical [RuCl2(CO)3DMSO]
monomers (2). Next, 2 further reacts with DMSO to yield [RuCl2(CO)2-(DMSO)] isomers (3a,3b) with concomitant release
of CO. Alternatively, the carbonyl ligands can react with water to give carboxylates (4a–c). Adapted from [24].
However, since CORM-2, not CORM-3, is by far the pre-eminent and commercially
affordable CORM for biological research, we describe now new studies of its CO release in
relation to its antimicrobial potential and of its interactions with amino acids and metabolic
thiols: we conclude that the term ‘CO-releasing molecule’ is, in many experimental designs,
a misnomer.
2. Materials and Methods
2.1. Preparation of CORM-2 Stocks
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-
Aldrich (Poole, UK). CORM-2 dimer Ru2Cl4(CO)6 (tricarbonyldichlororuthenium(II)) was
purchased from Sigma-Aldrich (Poole, UK). and dissolved in dimethyl sulfoxide (DMSO)
to final concentrations of 10–40 mM. Stocks were further diluted to <10 mM with distilled
H2O. CORM-2 solutions were shielded from light and, with the exception of intentionally
prolonged CO-release experiments (described below), used within 10–15 min of dissolution.
For assessment of the effects of growth media on CORM-2 antimicrobial activity, 10 mM
CORM-2 stocks were prepared in DMSO and then diluted 10-fold with either sterile H2O
(as standard), 10 mM phosphate-buffered saline (PBS), glucose-defined minimal medium
(GDMM), Luria broth (LB), Mueller Hinton II broth (MH-II), Dulbecco’s modified Eagle
medium (DMEM) or Roswell Park Memorial Institute medium (RPMI) as described be-
fore [28]. The resulting CORM/media solutions were incubated at room temperature for
10 min and added to bacterial cultures to a final concentration of 30 µM CORM-2 and
5% (v/v) medium, meaning that the DMSO concentration was generally 0.3% in these
experiments. To study the effects of exogenous amino acids, sulphur compounds or nu-
cleotide monophosphates on CORM-2 antimicrobial activity, the procedure employed was
as previously described [27]. Briefly, 10–40 mM CORM-2 stocks, prepared in DMSO, were
incubated with a 2-fold excess of individual amino acids, sulfur compounds (glutathione
(GSH), oxidised glutathione (GSSG), sodium hydrosulphide, N-acetyl-cysteine (NAC)) or
nucleotide monophosphates (AMP, CMP, GMP or TMP). The resulting solutions were incu-
bated at room temperature prior to addition to bacterial cultures to a final concentration of
30 µM CORM-2 (maximum 0.3% DMSO) and 60 µM amino acid, sulphur compound or
nucleotide monophosphate.
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2.2. CO-Release Measurements (Oxyhaemoglobin and Oxyneuroglobin Assays)
Measurements of CO release from CORM-2 stock solutions were conducted via oxy-
haemoglobin assays as outlined before [26]. Briefly, bovine haemoglobin (Hb) in 0.1 M KPi
buffer pH 7.4 was reduced by the addition of excess sodium dithionite and then desalted on
a PD-25 column (GE Healthcare, Little Chalfont, UK) to obtain oxyhaemoglobin (oxyHb).
Release of CO from CORM-2 was observed by changes in the Soret region (~422 nm) of
the oxyHb visible absorbance spectrum following displacement of the bound O2 by CO
to yield carbonmonoxy-haemoglobin (COHb). Stock solutions of CORM-2 (10 mM) were
prepared in DMSO and then added to ~12–13 µM oxyHb to a final concentration of 100 µM
CORM-2. The solutions were then incubated for 2 min and CO-difference spectra were
measured using the spectrum of the oxyHb sample as a baseline. Essentially identical
methods were used with purified neuroglobin [29], kindly provided by Dr Jesus Tejero,
University of Pittsburgh. Prior to each CORM-2 addition at the ages after DMSO disso-
lution shown in Figure 2, the level of autoxidation of the oxygenated form was checked
in visible spectra and found to be insignificant. It is important to note that, under our
conditions, CO released from CORM-2 never saturated the oxygenated globins used as
sensors. The amount of carbonmonoxy globin in the samples resulting from CO released
from CORM-2 was then quantified from published extinction coefficients and comparison
with the CO-difference spectra of the sample obtained by saturation with CO gas for 2 min.
Between time points, CORM-2 stocks were stored shielded from light and were mixed
prior to addition to oxyHb.
2.3. General Bacterial Methods and Strains
Bacterial strains employed in this study were E. coli K-12 strain MG1655 (F− lambda−
ilvG, rfb-50, rph-1) and a GSH-deficient derivative strain (E. coli MG1655 gshA) which
contained a kanamycin resistance cassette in place of the gene for gshA encoding a γ-
glutamate-cysteine ligase. Correct insertion of the KanR cassette was confirmed by PCR
and measurements of total cellular thiol content via 5,5-dithio-bis-(2-nitrobenzoic acid)
(DTNB) assays of cell-free extracts, essentially as described before [30]. Growth of E. coli
cultures was assessed via standard methods using either optical density measurements in a
Jenway 7305 spectrophotometer (Felstead, UK) at 600 nm or in a Tecan Sunrise Plate reader
(Thermo Fisher Scientific, Horsham, UK). Viability counts were made using the Miles–
Misra method [31]. Strains were routinely grown aerobically at 37 ◦C in the phosphate
salts-based glucose-defined minimal medium (GDMM) [32].
2.4. Assessment of CORM-2 Accumulation and Subcellular Distribution
CORM-2 accumulation by E. coli cells was determined by measuring Ru content of
E. coli cell pellets following exposure to CORM-2 by inductively-coupled plasma-atomic
emission spectroscopy (ICP-AES), as described previously [27,33]. We used washes of
0.5% nitric acid to remove extraneous metal [34], but it is not possible to discriminate
unambiguously between loosely bound and tightly bound metal. To determine subcellular
localisation of CORM-derived Ru, early exponential phase E. coli cultures were treated with
30 µM CORM-2 for 1 h and then harvested by centrifugation at 5000× g for 20 min at 4 ◦C.
Supernatant samples containing excess CORM-2 were discarded. Pellets were washed in
ice-cold phosphate-buffered saline to remove loosely associated CORM-2 and a fraction
was retained for determination of Ru content of the whole cellular fraction. Next, cell
pellets were resuspended in 50 mM Tris-HCl (pH 8.0) and broken by sonication. Unbroken
cells/debris were removed by a low-spin centrifugation (15,000× g) to obtain cell lysates.
The unbroken cells and debris were analysed by ICP-AES for the ‘debris’ fraction. Cell
lysates were then subjected to a high-spin ultracentrifugation (215,000× g for 1 h at 4 ◦C)
to obtain an insoluble membrane pellet (containing both inner and outer membranes) and
a soluble cytoplasmic/periplasmic fraction. Each fraction was prepared for ICP-AES as
described before [27,33]. For determination of Ru content of E. coli genomic DNA, cell
cultures were treated with 30 µM CORM-2 as described above, washed to remove excess
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CORM-2 and then genomic DNA was extracted using the Wizard Genomic DNA Extraction
Kit (Promega, Southampton, UK) as per manufacturer’s instructions. DNA was quantified
via a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Horsham, UK) and
then genomic DNA samples were analysed for Ru content by ICP-AES.
μ
Figure 2. Little CO is released from CORM-2 in DMSO. (I) CO-difference UV-visible spectrum of CO-saturated haemoglobin
with the absolute spectrum of the oxyHb sample (shown in inset) as a baseline. (II) Amount of CO detected as COHb
expressed as a function of the age of the CORM-2 stock solution, i.e., time after dissolution of CORM-2 in DMSO (solvent).
(III) Maximum yields of Mb-CO from 10 µM CORM-2 as an average of two technical repeats, with SD shown as error bars.
CO was detected after prior incubation for 20 min in a 10-fold excess of DMSO, water, KPi, GDMM, MH-II, LB, DMEM
or RPMI. (IV) CO-difference UV-visible spectrum of neuroglobin with saturating CORM-2. The inset shows the absolute
spectra of the reduced (dotted) and CO-bound forms (green). (V) Amount of CO detected as CO-Ngb expressed as a
function of the age of the CORM-2 stock solution, i.e., time after dissolution of CORM-2 in DMSO. Data in II and V display
individual data points from 3 independent replicates. Minimal autoxidation of the oxyglobins was established prior to each
time point in II and V.
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2.5. Interactions of CORM-2 with Amino Acids or Glutathione Via 1H NMR
Synthetic peptides (Genscript, Leiden, Netherlands) A3CA3, A3DA3, A3HA3, A3MA3
and A7 had N-terminal acetylation and C-terminal amidation.
1H NMR experiments were
conducted in 30 mM KPi buffer prepared in distilled H2O at pH 7.4 then freeze-dried and
re-dissolved in deuterated water (D2O) prior to experiments. Stock solutions of peptides
were generally prepared in 30 mM KPi buffer pH 7.4 but peptides with low solubility were
dissolved in deuterated DMSO (d6-DMSO) and further diluted with buffer. A maximum
of 10% (v/v) d6-DMSO was present during titration experiments. CORM-2 stocks were
prepared in d6-DMSO and then further diluted 10-fold in D2O and typically used within
1–2 h. Peptide concentrations were determined by 1H NMR relative to the internal standard
trimethylsilylpropionate (TSP, 100 µM) using a long recycle time. Titrations with reduced
glutathione (GSH) or oxidised glutathione (GSSG) were conducted as for synthetic peptides.
For titrations, peptide or glutathione solutions were prepared and quantified prior to the
addition of CORM-2 or the equivalent level of d6-DMSO as a control for the solvent.
1H NMR experiments were carried out on a Bruker Avance-1 800 MHz spectrometer
(Coventry, UK) using pre-saturation for solvent suppression. Baselines were corrected
manually before spectral signals were integrated using Bruker Topspin software version
4.0.5 (Coventry UK). Estimations for CORM peptide-binding affinities, expressed as the
dissociation constant, Kd, were determined as described [27,35], based either on integrated
peak intensity (slow exchange conditions) or on chemical shift (fast exchange conditions),
using the following equation:
∆δobs = ∆δmax [([P]t + [L]t + Kd) − [([P]t + [L]t + Kd)
2 − 4[P]t [L]t]
1
2 ]/2[P]t (1)
where: ∆δobs is the change in the observed shift from the free state and ∆δmax is the
maximum shift change in saturation, and [P] and [L] represent the concentrations of free
protein and free ligand. Kd is the concentration of ligand and protein required to saturate
half the binding sites.
2.6. ATP Release Assays
The levels of extracellular ATP in E. coli cultures grown with or without CORM-2 were
determined as follows. Culture samples were rapidly harvested by brief centrifugation at
15,000× g at 4 ◦C to remove cells. Supernatants were retained at −20 ◦C. ATP analysis of
the extracellular supernatants was conducted using the bioluminescence-based Molecular
Probes ATP Determination Kit (Invitrogen, Thermo Fisher Scientific, Horsham, UK). The
levels of ATP in the supernatants were derived via a standard curve of ATP solutions
from 1 nM–1 µM. Luminescence measurements were measured in duplicate on a Lumat3
Luminometer (Berthold Technologies, Harpenden, UK).
2.7. Data and Statistical Analysis
All biological experiments were conducted with a minimum of three biological repeats
and often 2 or more technical repeats. General data handling and determination of means
and standard deviations were performed in Microsoft Excel. Statistical analyses (ANOVAs,
Tukey’s multiple comparisons tests, t-tests, Pearson’s correlational analysis) and the fitting
of data to standard curves were conducted in GraphPad Prism Software.
3. Results
3.1. CORM-2 Releases Negligible Amounts of CO in Biological Experiments
Unlike CORM-3, which is water-soluble, CORM-2 requires solubilisation in DMSO
where it undergoes extensive ligand exchange with the solvent and isomerises with impli-
cations for CO release (Figure 1). CO is liberated by ligand substitution by DMSO in steps
3a and 3b (Figure 1) but the stoichiometry between 2, 3a and 3b is uncertain [21,22]; species
4a, 4b and 4c show possible further reactions with water to form carboxylates. Thus the
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complexity of the dissolution of CORM-2 in DMSO frustrates understanding the amount
of biologically accessible CO and is likely to depend on the age of the stock solution.
The classification [25] of CORM-2 as a ‘fast CO releaser’ was based on its ability
to convert ferrous myoglobin to carbonmonoxy myoglobin. This assay requires sodium
dithionite to reduce myoglobin, but dithionite (and also sodium sulphite and potassium
metabisulphite) facilitate the release of CO [26]. Here, we used three different globins to
investigate CO release and inform our studies of the mechanism of CORM-2 toxicity.
To investigate CO release from CORM-2 in DMSO, but avoid dithionite, we measured
CO release from CORM-2 at various intervals after dissolution in DMSO by conversion of
two oxygenated globins—oxyhaemoglobin (oxyHb) and oxyneuroglobin (oxyNgb)—into
the respective carbonmonoxy forms; these assays obviate the need for dithionite because,
unlike myoglobin, these globins bind CO with much greater affinities than they bind
oxygen [29,36], and so it is not necessary to deoxygenate reduced globin solutions to
measure the CO release kinetics of CORMs.
The amount of CO liberated was quantified via the optical changes that occur as CO
displaces O2 bound to the globins after addition of CORM-2 (26). The spectral features
of the reaction of haemoglobin with CO in saturated solutions are shown in Figure 2I.
Figure 2II shows the use of this assay to determine the level of CO released from CORM-2
stocks at intervals of ‘aging’ after dissolution in DMSO. Detectable CO, initially approx.
10% of the available CO, decreased rapidly over time (Figure 2II); less than 0.05 mol CO per
CORM-2 dimer was measured after 20 min. Strikingly, the maximum level of CO released
from CORM-2 was approximately 0.1 mol CO per mol CORM-2, occurring at 5–10 min
after dissolution in DMSO.
Second, to assess whether the use of various growth media in future experiments might
interfere with CO release, we measured the amount of CO generated by CORM-2 via the
widely used assay involving conversion of deoxymyoglobin (Mb) to carbonmonoxymyo-
globin (MbCO) in the presence of dithionite to promote CO release [26]. Figure 2III shows
that the level of CO released from CORM-2 following pre-incubation in DMSO or water
was 0.44–0.55 equivalents. There were no significant differences observed when CORM-2
was preincubated with phosphate buffer (KPi), a defined growth medium (GDMM), or any
of a range of complex growth media (see Figure 2III). Therefore, we conclude that these
rich nutrient media do not interfere with CO release (see later).
Human haemoglobin has an affinity for CO approximately 200–250 times greater
than for oxygen [36,37]. Nevertheless, to assess the potential availability in vivo of a
presumptive higher-affinity site for binding of CO from CORM-2, we used neuroglobin
(Ngb), which is expressed in brain and retina and has an affinity for CO 500 times higher
than haemoglobin. The distinct optical changes that occur on reaction of oxyneuroglobin
with CO (Figure 2IV) allowed confirmation of the level of CO released from CORM-2
on ‘aging’ in DMSO. The highest occupancy of CO was at 5 min after preparation of the
CORM-2 (Figure 2V) and accounted for about 7% of the available CO if one CO were
released in stages 3a and 3b of Figure 1. Thus, in the experiments conducted in this study,
without dithionite, we estimate that only a maximum of ~0.07 to 0.1 mol CO per CORM-2
was present during the microbiological studies. Thus, in experiments using CORM-2 as a
source of CO, the time interval between dissolution in DMSO and experimental use should
be as short as possible and no longer than about 10–15 min, to avoid even lower levels of
available CO.
Although it would be desirable to measure independently the Kd of CORM-2 for
CO, this would be extremely problematic. As shown above, the CORM-2 dimer, when
dissolved, is solvated to break into monomers. It would be difficult to resolve the kinetics
of CO release and rebinding. When CORM-2 is dissolved in water, CO2 is formed, giving
an additional complication [22]. Finally, in water the Cl− is replaced by water. We therefore
believe that useful kinetic studies are fraught with difficulties and they were not attempted.
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3.2. CORM-2 Exhibits Ru-Related Antimicrobial Activity Against Escherichia coli
CORM-2 caused dose-dependent (7.5–100 µM) inhibition of growth of E. coli MG1655
(Figure 3I) grown aerobically on minimal salts-based medium (glucose-defined minimal
medium, GDMM). Based on data in Figure 2, the amount of CO released was estimated to
be <10 µM (corresponding to 10% of the CORM-2 concentration after 4 h growth), much too
low to have significant toxic effects [38]. Bactericidal effects were observed at 15–100 µM
CORM-2 (Figure 3II). Thus, subsequent experiments in this study focused on the role of








































































































































































Figure 3. The antimicrobial activity of CORM-2 against E. coli is strongly correlated with intracellular Ru accumulation. The
dose-dependent inhibitory effects of CORM-2 (0–100 µM) on E. coli growth (I) and viability (II) as determined by measuring
optical density (OD600) and colony-forming units (CFU). Uptake of CORM-2 (III) was assessed by measuring cellular Ru
content at time intervals after addition of 30 µM CORM to early log-phase E. coli. The viability (IV) of E. coli cultures 1 h
after addition of 0–30 µM CORM-2 was compared to the level of intracellular Ru (V). The data in IV and V are plotted in VI
to show the negative correlation between the culture viability and the extent of Ru accumulation (r2 = 0.92). Cells were
grown on GDMM in all experiments. Cellular Ru content was assessed by conducting ICP-AES on culture samples. Data
represent three biological repeats ± standard deviation (SD) and the data in (VI) were analysed via a Pearson’s (two-tailed)
correlational analysis (p ≤ 0.0001).
Next, we measured the Ru contents of E. coli cell pellets via inductively coupled plasma-
absorption emission spectroscopy (ICP-AES) at time intervals after addition of 30 µM CORM-
2 (Figure 3III). Initial uptake of Ru by E. coli cells occurred at ~250 µM Ru min−1 and
reached a final intracellular concentration of ~2 mM after 60 min, approx. 60-fold higher than
extracellular concentrations. To determine whether cellular accumulation of Ru was related
to loss of culture viability, cell cultures were incubated for 1 h with 7.5–30 µM CORM-2 and
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then corresponding samples were tested for viability (Figure 3IV) and cellular Ru content
(Figure 3V). There was a strong negative correlation between the viability of cell cultures
and the extent of cellular Ru accumulation (r2 = 0.92), implying that the antimicrobial
effects of CORM-2 are linked to the accumulation of Ru (Figure 3VI).
A fraction of the accumulation of Ru observed in Figure 3 might be accounted for
by adsorption to the surface of the cells. This confounds virtually all studies of metal
compound uptake by bacteria because of the net negative charge of the surface layers.
To mitigate this, we washed cells with nitric acid but cannot unambiguously distinguish
between loosely bound and tightly bound metal. Nevertheless, in a test of the efficacy of
1% nitric acid in removing loosely bound Ru, we found no significant difference between
the Ru content of cells washed three times in acid or once in 10 mM K phosphate buffer
(results not shown). Although the relatively basic subcellular fractionation procedures
used may include externally exposed layers in the membrane and debris fractions, the
appearance of Ru in extracted DNA (see later) demonstrates that Ru does enter cells. Thus,
much of the accumulated ruthenium in the ‘soluble’ fraction is probably bound to DNA.
3.3. Exogenous Amino Acids and Thiol Compounds in Rich Media Overcome Inhibition of E. coli
Growth by CORM-2
Amino acids and peptides are major components of rich nutrient broths. Supplemen-
tation of GDMM with only 0.25% (w/v) casamino acids (a casein hydrolysate) dramatically
reduced the potency of CORM-2 against E. coli so that total inhibition of growth now
required 250 µM CORM-2 (Figure 4III). Next, we identified which specific amino acids
were responsible for such effects (Figure 4IV–VII). As before, E. coli cells were grown to
early exponential phase in GDMM prior to addition of 30 µM CORM-2 that had been
pre-incubated for 10 min with each amino acid. A two-fold excess of exogenous Cys, Met
or His provided significant protection against the growth inhibitory effects of CORM-2
(Figure 4V,VII). Thiol-containing cysteine exhibited the most complete growth protection
and so we investigated whether a two-fold excess of other sulphur compounds (namely
reduced GSH, NAC, sodium hydrosulphide (NaHS), GSSG, cystine (i.e., Cys(Ox)) could
also protect cells against 30 µM CORM-2 (Figure 4VIII–IX). As with cysteine, exogenous
reduced thiol-containing GSH, NAC and NaHS were sufficient to fully protect cells against
CORM-2-induced growth inhibition, whereas oxidised thiol-containing species (GSSG and
Cys(Ox)) gave only partial growth protection, similar to His and Met.
3.4. Chelation of CORM-2 by Exogenous Cys, His and Met Prevents Accumulation of Bactericidal
Ru(II) into E. coli
Chelation of non-essential antimicrobial metal ions (e.g., Ag(I)) by exogenous amino
acids, peptides or ions within the extracellular milieu is known to reduce their antimicrobial
effects by preventing access of the metal ion to metal-sensitive intracellular targets [39]. To
investigate whether the protective effects of exogenous Cys, His and Met against CORM-2
could be due to chelation of the compound by these amino acids, we investigated cellular
Ru(II) accumulation in E. coli cells exposed to 30 µM CORM-2 that had been pre-incubated
with a two-fold excess of water (control), Cys, His, Met, Asp or Ala (Figure 5I). At 20 and
80 min after CORM addition, exogenous Cys and His dramatically reduced cellular Ru
accumulation relative to CORM only-treated cells (Figure 5I). As a result, cells exposed to
a combination of CORM-2 + Cys or CORM-2 + His showed no significant loss of culture
viability relative to the non-treated control (Figure 5II). A two-fold excess of Asp or Ala did
not prevent Ru accumulation (Figure 5I) and, as expected, did not prevent loss of culture
viability in response to CORM-2 (Figure 5II). Interestingly, although a two-fold excess of
Met prevented loss of culture viability (Figure 5II), the reduction in cellular accumulation
of Ru was minimal (Figure 5I). Taken together, it appears that exogenous Cys and His
prevent CORM-2-derived Ru accumulation and thus act as extracellular chelating agents
to protect cells against CORM-2-related metal toxicity, whereas exogenous Met may act via
a different mechanism.









































































































































































































































































Figure 4. The potency of CORM-2 is influenced by certain compounds added to the growth medium. (I,II) CORM-2 stocks
were prepared by dilution in 10% DMSO/90% H2O (‘CORM-2
′) or diluted in 10% DMSO/90% medium: (I) minimal
salts-based media (phosphate-buffered saline, PBS, glucose-defined minimal medium, GDMM) or (II) rich nutrient broths
(lysogeny broth, LB, Mueller-Hinton II, MH-II, Dulbecco’s modified Eagle medium, DMEM or Roswell Park Memorial
Institute medium, RPMI) and left to incubate for 10 min. These stocks were then added at a CORM-2 concentration of 30 µM
to E. coli grown on GDMM (arrow). Growth (OD595) was monitored thereafter. Rich growth media (II) protected cells from
the growth inhibitory effects of 30 µM CORM-2. In (III), cultures grown on GDMM were supplemented with 0.25% (w/v)
casamino acids, and 0–500 µM CORM-2 was added to determine whether a mixture of extracellular amino acids protects
against CORM-2-mediated growth inhibition. To determine which specific components of rich media were responsible
for protective effects against CORM-2-induced growth inhibition, CORM-2 stocks were mixed with a 2-fold excess of
(IV) non-polar amino acids, (V) polar, uncharged amino acids, (VI) aromatic amino acids, (VII) polar charged amino acids,
(VIII) reduced thiol compounds (N-acetyl cysteine, NAC, reduced glutathione, GSH, sodium hydrosulphide, NaHS) or
(IX) oxidised thiol compounds (cystine, OxCys, oxidised glutathione, GSSG). These stocks were then added to E. coli cells
grown on GDMM and growth was monitored relative to no-CORM controls (dashed line) and 30 µM CORM-2 prepared by
dilution in 10% DMSO/90% H2O as standard (grey line). The lines in red indicate amino acids/sulphur compounds that
protect against the growth inhibitory effects of 30 µM CORM-2, whereas black lines indicate that the compounds did not
exert protective effects. All data are representative of 3–4 biological repeats ± SD.










Figure 5. Extracellular amino acids protect E. coli against CORM-2, reduce Ru accumulation and in vitro have high
affinities for CORM-2. I,II. Cys, His and, to a lesser extent, Met protect cells against CORM-2 toxicity and prevent
intracellular Ru accumulation. CORM-2 stock solutions were incubated with a 2-fold excess of each amino acid prior
to addition of CORM-2/amino acid mixtures (30 µM CORM-2, final concentration) to cultures. Extracellular Cys and
His significantly reduced the extent of CORM-induced intracellular Ru accumulation (I); Cys, His and Met exerted a
dramatic reduction in CORM-2-induced cytotoxicity (II) (grey line) and restored viability to that of the control (dashed line)
(* p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, assessed via unpaired t-test). Data in I and II represent 3 biological repeats, shown as
mean ± SD. (III,IV) Attenuation of toxicity correlates with CORM-2 binding affinities for synthetic peptides containing Cys,
His or Met as assessed via 1H NMR. The nature of the interactions between CORM-2 and these amino acids was assessed by
1H NMR titrations of synthetic peptides (A3XA3) with CORM-2 or solvent (10% d6-DMSO/90% D2O), where X = Cys (C),
His (H) or Met (M). (III left) Overlaid 1H NMR spectra of A3CA3 (78.5 µM), showing the Cys Hβ signal titrated with
0–82.4 µM CORM-2 or equivalent volume of solvent. (III middle) Overlaid 1H NMR spectra of A3HA3 125 µM showing
the histidine imidazole ring protons titrated with 0–500 µM CORM-2 or equivalent volume of solvent. (III right) Overlaid
1H NMR spectra of A3MA3 peptide (78.5 µM) showing the Met Hε protons titrated with 0–4690 µM CORM-2 or equivalent
volume of solvent. In each titration the arrow shows the direction of increasing [CORM-2]. (IV) Binding curves of the
decrease in intensity of 1H NMR signals corresponding to Cys, His or Met (as shown in III) upon increasing additions of
CORM-2. The estimated Kd of CORM-2 to each peptide was determined to be: 0.3 ± 1 µM for Cys, 130 ± 25 µM for His,
4700 ± 1000 µM for Met. Titrations were performed in 30 mM KPi buffer pH 7.4 and pH was maintained by adjustment
with KOH throughout the experiment.
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3.5. CORM-2 Binds with High Affinity to Cys, His and to a Lesser Extent Met as Investigated by
1H NMR
In order to characterise direct interactions of amino acid sidechains with CORM-2,
NMR titrations were undertaken, titrating CORM-2 into solutions of N- and C-terminally
blocked peptides AAAXAAA, where X is Cys, His, Met, Asp or Ala. Because CORM-2
is made up as a stock solution in DMSO and subsequently diluted in water before use,
control titrations were carried out using the same concentrations of DMSO but without
CORM-2 present (i.e., adding 10% DMSO in water). Addition to the cysteine-containing
peptide produced a loss of signal intensity from the cysteine sidechains (Figure 5III), with an
increase in intensity of several new signals. The nature of these species may warrant further
study but is beyond the scope of the present objectives. This implies a slow dissociation
rate of the bound CORM-2-derived ligand from the cysteine, and also implies that there is
more than one bound species. This was expected, based not only on the different possible
Ru-based ligands indicated in Figure 1, but also on the complex solution chemistry of
ruthenium carbonyl complexes in water. We showed previously [27] that CORM-3 reacts
with phosphate buffer, and also undergoes attack of hydroxide ions on the CO ligands
to produce bound carboxylate species, known as the Water Gas Shift reaction [40]. One
would expect similar solution chemistry for CORM-2. The signal intensity can be fitted to a
standard binding isotherm [35] to produce a fitted dissociation constant of 0.3 µM. There is
a large fractional error on this value, because the affinity is strong (the Kd for the ligand is
similar to the concentration of the target) and towards the extremity of what can be reliably
fitted by NMR, but clearly cysteine binds tightly to CORM-2. Saturation occurs at a ratio of
two Ru to one cysteine, i.e., both ruthenium atoms are available for binding.
Titrations with the other peptides show progressively weaker binding for histidine
and methionine, with slow exchange for His and intermediate exchange for methionine,
in line with their weaker affinities (Figure 5IV). Peptides containing aspartate or alanine
showed changes indistinguishable from control DMSO titrations (Figure 5III). The mea-
sured binding affinities are therefore entirely consistent with the observed effectiveness of
each of the amino acids on Ru accumulation (Figure 5I) and toxicity (Figure 5II), namely
Cys >> His > Met, with no effect for Asp or Ala.
3.6. Glutathione Is a Key Extracellular Reactant with CORM-2 and an Intracellular Target of
CORM-2-Derived Ru(II)
In view of the CORM-2-binding propensity of thiols (Figure 5) and the abundance in
cells of the thiol tripeptide GSH [41], we tested the protective effects in bacterial cultures
of GSH and oxidised glutathione, GSSG. When included in growing cultures, GSH, and
to a slightly lesser extent GSSG, fully protected cells from CORM-2 toxicity (Figure 6I).
By pre-incubating the CORM-2 stock solution with these agents it was quantitatively
confirmed that GSH was more effective than GSSG in preventing uptake of Ru (Figure 6II).
A GSH-deficient mutant (gshA) also accumulated significantly less Ru than an isogenic
parent strain (Figure 6III) and was hypersensitive to CORM-2 when added to growing
cultures (Figure 6IV); the basis of this diminished Ru accumulation is not known and there
is no evidence that GSH facilitates Ru compound transport (see Discussion). However, any
activity inside a cell that removes a transported substrate will enhance its uptake simply
by removing the product of transport. Thus, the observation that lowering the internal
concentration of GSH is accompanied by diminution of Ru uptake is consistent with GSH
being one of the internal targets for ruthenium. Ru uptake is not abolished because, as we
show, there are many other targets additional to GSH. Collectively, these data show the
importance of the natural thiol GSH in modulating CORM-2 toxicity. We have not shown
that glutathione is the sole intracellular target of CORM but GSH is the most abundant
intracellular thiol, reaching c. 10 mM (e.g., [42]).












Figure 6. Glutathione is an important intracellular and extracellular target of CORM-2 (I–IV) and CORM-2 has a much
higher affinity for reduced glutathione (GSH) than oxidised glutathione (GSSG) as investigated by 1H NMR (V–VIII). In
I, the effects are shown of extracellular reduced glutathione (GSH) or oxidised glutathione (GSSG). The grey line shows
cell viability with CORM-2 alone. GSH fully restored viability to that of the no-CORM control (dashed line). II shows
CORM-induced intracellular Ru accumulation in the absence or presence of GSH or GSSG (* p ≤ 0.05, ** p ≤ 0.01, assessed
via unpaired t-test). CORM-2 stocks were incubated with a 2-fold excess of the compound prior to addition of 30 µM
CORM-2. (III) Uptake of CORM-2-derived Ru is significantly reduced in a glutathione-deficient mutant (gshA, open
symbols, dashed line) compared to the GshA+ wild-type parent strain (gshA+, solid line) (* p ≤ 0.05, *** p ≤ 0.001, assessed
via unpaired t-test). (IV) Culture viability (CFU mL−1) of the glutathione-deficient strain compared to the parent strain
following addition of 7.5 or 15 µM CORM-2. Data in I–IV represent 3 biological repeats ± SD. (V) NMR spectra of the
Cys Hβ resonances of GSH (1 mM) on titration with 0–5 mM CORM-2 and (VI) corresponding binding curve. (VII) NMR
spectra of the Cys Hβ resonances of GSSG (0.5 mM) on titration with 0–14.5 mM CORM-2 and (VIII) corresponding binding
curve. In each titration the arrow shows the direction of increasing [CORM-2]. The estimated Kd of CORM-2 to GSH was
determined to be: 2 ± 1 µM for GSH (VI) and 25 ± 5 mM for GSSG (VIII). Titrations were performed in 30 mM KPi buffer
pH 7.4 and pH was maintained by adjustment with KOH throughout the experiment.
As expected, the Ru ion of CORM-2 bound tightly to GSH (Figure 6V,VI Kd ≈ 2 µM)
but much more weakly to GSSG (Figure 6VII,VIII, Kd ≈ 25 mM). The difference in these
NMR titrations confirms the importance of the free thiol group in GSH in the reaction
with CORM-2.
3.7. CORM-2-Derived Ru(II) Has Multiple Membrane and Intracellular Targets in E. coli Cells
Ruthenium is not a naturally occurring element in biology and its uptake is therefore
readily and sensitively assayed by ICP-AES (Figure 7). We exposed growing cultures to
30 µM CORM-2 and prepared crude subcellular fractions, namely cytoplasm (‘soluble’),
total cell membranes and debris from the breakage and fractionation procedures (Figure 7I).
The metal ion was found to be equally distributed between cytoplasm and membranes
(Figure 7II). Chromosomal DNA bound almost three atoms of Ru per 1000 bp (Figure 7III).
In light of the binding of Ru to membranes, we hypothesised that the acute toxicity of
CORM-2 might be attributable to membrane damage, leading ultimately to cell lysis. To
assay lysis, we measured leakage of ATP from bacteria treated with CORM-2 at sub-toxic
and toxic concentrations, exploiting the fact that ATP is generated only in the cytoplasm and
not normally exported [43]. A CORM-2 concentration of 15 µM was highly toxic as judged
by cessation of growth (Figure 7(IVa)) and rapid loss of cell viability (Figure 7(IVa,IVb)).
However, 7.5 µM CORM-2 was only slightly inhibitory to growth (Figure 7(IVa)) and
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was without major effects on cell viability (Figure 7(IVa,IVb)). Nevertheless, 7.5 µM
CORM-2 elicited substantial leakage of ATP from inside cells, indicating extensive cell lysis
(Figure 7(IVc)). Surprisingly, 15 µM elicited less ATP leakage. One possibility is that lower
CORM-2 concentrations allow continued cellular metabolism while poisoning cells and
producing membrane damage, but higher CORM-2 concentrations kill cells more rapidly







μ μ ≤ ≤
Figure 7. Subcellular distribution of CORM-2-derived Ru(II). (I) Scheme demonstrating the process for preparation of
subcellular fractions of E. coli for quantification of Ru content by ICP-AES. (II) The Ru content of each subcellular fraction
displaying the percentage of total Ru recovered in each fraction by ICP-AES. (III) Localisation of CORM-2-derived Ru on E.
coli chromosomal DNA. (IIIa) the amount of chromosomal DNA recovered from 20 mL E. coli cell cultures before (black
bar) and after 1 h incubation with 30 µM CORM-2 (white bar). (IIIb) the amount of Ru (ng) detected per µg of DNA as
determined by ICP-AES of chromosomal DNA samples from cells treated for 1 h with 30 µM CORM-2 and the amount of
atoms of Ru per kbp of DNA. (IV) Sub-toxic doses of CORM-2 cause ATP leakage from E. coli cells. The extent of growth
inhibition (IVa) and loss in cellular viability (IVb) upon addition of 0–15 µM CORM-2 (t = 0 h) to E. coli cultures grown
on GDMM. (IVc) Amount of ATP (nM) detected in the supernatant of E. coli cells upon exposure to no CORM, DMSO or
sub-toxic (7.5 µM) or toxic (15 µM) levels of CORM-2 (** = p ≤ 0.01, *** = p ≤ 0.001). All data in II–IV are representative of 3
biological repeats ± SD. Significance differences were assessed via unpaired t-tests.
4. Discussion
CORM-3 and CORM-2 are generally considered primarily CO carriers or ‘Trojan
Horses’ [33,44,45], delivering a toxic cargo of CO, with the residual Ru ion(s) contributing
only a minor role in antimicrobial activity (Figure 8). Other investigators have suggested
that antimicrobial activity is due in part to generation of reactive oxygen species, perhaps
following respiratory inhibition [46,47]. Recently, a further proposal for CORM-3 toxicity
in bacteria has been advanced [48], namely that it elicits intracellular glutamate deficiency
and inhibition of nitrogen and tricarboxylic acid cycles. Unlike the present findings, this
was attributed to the released CO, but how the gas inhibited glutamate synthesis and iron–
sulphur enzymes of the tricarboxylic acid cycle was not established. This conclusion was,
however, consistent with the detection of CO within bacteria using the turn-on fluorescent
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probe COP-1 [49] and the formation of intrabacterial oxidase–CO adducts [23,45], but not
readily compatible with the findings from two laboratories that even high CO concentra-
tions in growth media are not toxic [38,50]. Another important unresolved issue in the
potential application of CORMs as antimicrobial drugs is why CORM-2 possesses potent
antimicrobial activity, yet is reportedly non-toxic to mammalian cells, ex vivo and in whole-
animal models, where it exerts therapeutic (including vasodilatory, anti-inflammatory and
cardioprotective) effects [19,51–54].
Figure 8. Complexity of the antibacterial actions of CORM-2. The grey background shows the surface view of a bacterial
cell with flagella. The orange and white assembly represents phospholipid bilayer in the inner cell membrane containing the
respiratory chain (green ovals) and numerous other proteins. The red shapes represent membrane and soluble proteins with
exposed -SH groups (exposed histidine imidazole or methionine CH3S- are not shown). The blue circles show the charge
separation (positive outside, i.e., the protonmotive force) established via respiratory electron transfer or ATP hydrolysis.
In the presence of the solvent, DMSO, numerous species are formed by DMSO displacement (1) with low yields of CO,
rapidly declining with time (2). Exogenous amino acids and thiols (especially cysteine, glutathione and N-acetyl cysteine)
bind CORM-2 and thus protect bacteria from growth inhibition (3); the prevention of toxicity correlates with their CORM-2-
binding affinities. CORM-2 or its derived isomers enter cells by unidentified pathways (4). Glutathione and other thiols are
intracellular targets of CORM-2 (5). Residual CO inhibits terminal oxidase activity (6) but also may react with transcription
factors, Fe–S clusters and other unidentified targets (not shown), leading to loss of membrane integrity and cytoplasmic
ATP leakage (7). The fate of intracellular Ru(II) is complex but includes membrane (8) and other intracellular targets (9)
targets, including DNA (10).
One reason for the uncertainty in defining CORM-2 actions is the complex speciation
of CORM-2 in solvents (Figure 1). Since McLean et al. [26] found that the ‘fast CO release’
from Ru(CO)3L3 CORMs was due to reaction of the CORM with sulphites, such as sodium
dithionite (used as a strong reducing agent in the haemoglobin assay, but much stronger
than anything present in vivo), the levels of biologically available CO from CORM-2 or
CORM-3 have been unclear. Very little or no CO was detected upon the addition of CORM-
2 stocks to phosphate buffers or various growth media, in the absence of sodium dithionite,
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when analysed via diverse methods. An interesting recent report [55] notes slow release of
CO from liposomal CORM-2; however, the CO was detected using the myoglobin assay in
the presence of dithionite, and therefore it remains unclear whether the therapeutic benefit
was derived from CO release.
When CO release from CORM-2 was directly measured by FTIR in a sealed solution of
100% DMSO, a maximum of up to 0.4 mol of CO was released from CORM-2 [21], implying
that just 40% of CORM-2 dimer (Figure 1(1)) dissociated into species 3a and 3b and was
able to release CO. Rather, Seixas et al. found that approximately 1.8 mol of CO2 per CORM
could be detected in DMSO/aqueous solutions of CORM-2 [22]. This presumably occurs
via water–gas shift chemistry via attack of −OH on CO ligands of 2, 3a and 3b, and is
predicted to occur for CORM-3.
However, in the present study, we found that a maximum of 0.1 mol of CO per mol
CORM-2 dimer was available to bind oxyHb (Figure 2II). Even using Ngb, which has been
proposed as a useful ligand trap antidote for CO poisoning [29,56], we detected only 6–7%
of the CO potentially available from CORM-2 as the carboxyneuroglobin. The apparent
discrepancy between our findings and those of Klein [21] may be due to the different
methods to assay CO release, namely FTIR [21] and the oxyHb and oxyNgb assays (this
work). In our experiments, it is possible that some CO was lost to the atmosphere as
the CORM-2 stocks were added to globin solutions. Our conclusion is that, although
the exact mechanisms of CO release from CORM-2 are poorly defined quantitatively, it
is clear that only negligible amounts of CO are released in solution from CORM-2 in
biological experiments, even with such a high-affinity CO trap as Ngb. Only when harsh
sulphite-based reductants such as sodium dithionite are present is significant CO detectable.
Recently, we showed that CORM-3, Ru(CO)3Cl(glycinate), reacts with constituents of
biological growth media and buffers, resulting in the creation of numerous Ru(II)–carbonyl
species that do not release CO, even upon addition of dithionite. The biological actions of
CORM-3 against both bacterial and mammalian cells in vitro were instead shown to be due
to the reactivity of the Ru(II) ion, indicating that the designation of Ru(CO)3Cl(glycinate)
as a mere CO donor is misleading [27]. As CORM-3 is a derivative of CORM-2, we
decided to investigate whether the numerous reported biological activities of CORM-2
could instead be due to its Ru(II) ions rather than CO. Previously, Nielsen showed that
ruthenium in CORM-2, not CO, is the inhibitor of venom procoagulant activity [57,58],
while Dong et al. reported that CORM-2 activates cation currents in endothelial cells
independently of CO [59]. Similarly, a recent report [60] showed that both active CORM-2
and ‘inactive iCORM-2’ each exerted biological effects such as cyto- and genotoxicity,
antioxidant properties and the ability to induce the HO-1 gene. The released CO as well as
iCORM-2 were considered responsible for these effects.
The current data support the view that reaction of CORM-2 with sulphur-containing
molecules is similar to that observed for CORM-3 [27]. E. coli treated with 60 µM CORM-
2 plus cysteine or histidine exhibited no significant loss of viability, but were killed in
the absence of amino acids. Note that Southam et al. [27] used only a two-fold excess
of these amino acids in observing alleviation of CORM-3 toxicity, but a wider range of
supplements (cystine, glycine, serine, etc.) had to be used at concentrations up to 50 µM
(about 150-fold excess) to observe alleviation of toxicity [48]. In the present work, the
prevention of toxicity correlates with the CORM-2-binding affinities of these amino acids
as determined by 1H-NMR. Since GSH is the predominant thiol in many bacterial cells, it is
proposed to be an intracellular and extracellular target of CORM-2, with CORM-2 having a
much higher affinity for reduced glutathione (GSH) than oxidised glutathione (GSSG). Of
course, any intracellular protein with surface-exposed Cys, His or Met is also a plausible
target for CORM-2 and CORM-3. In this context, we note a recent paper [61] that reports
reactivity of both CORM-2 and CORM-3 with a range of compounds including GSSG. These
experiments used CORMs incubated for at least 2 h in aqueous buffer, which are likely
to have lost all CO by the start of the experiments. Furthermore, these experiments were
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done in vitro and therefore do not contribute directly to understanding the antimicrobial
toxicities of these CORMs.
When certain toxic metals are chelated outside the cell (as for Ag(I) [39]), their toxicity
is, unsurprisingly, reduced. Similarly, externally added Cys, His, Met or GSH allevi-
ate the toxicity of Ru–CORM-2 by preventing access of the Ru to the inside of the cell
(Figures 2 and 4, Figures 5 and 6), but the mechanism by which Ru–CORM-2 enters the cell
is unclear, especially since transcriptomic studies [62] have not identified any involvement
of transport proteins. We note that the formal positive charges on the Ru(II) entity of
CORM-2 are delocalised around an already hydrophobic molecule [63] that is likely to
penetrate the membrane by simple diffusion, reinforced by the existence of a pre-existing
electrical gradient, inside negative, maintained by respiration and/or ATP hydrolysis [64].
Whatever the mode of CORM transport (revealed in the Ru uptake assays), CO
release presumably occurs both outside and within cells. If, however, CORM-2 is applied
extracellularly in the presence of NAC, cysteine and other thiols, its antibacterial activity
is attenuated, and its uptake is inhibited [65]. If the thiol is assumed not to inhibit CO
release extracellularly (and we are unaware of any such evidence) and if the released CO
penetrates cells (as it will), then these experiments strongly support the view that it is not
CO, but the accumulated Ru, which is antibacterial. This conclusion is fully supported
by the fact that CO is not toxic to bacteria [38]. Interestingly, an oral carbon monoxide
release system (OCORS) is claimed to provide precise, controlled, tunable and targeted CO
delivery for the treatment of gastrointestinal diseases. OCORS is an oral tablet based on
sulphite-induced CO release from the CO-releasing molecule 2 (CORM-2) but toxicological
assessments are still needed [66].
The thiol–CORM-2 interactions we describe and/or CORM-2 toxicity may well limit
its therapeutic value as a CO delivery agent in mammalian systems, where high levels of
biological thiols are present. However, an early study [51] showed that neither CORM-2 nor
CORM-3 caused cytotoxicity in an in vitro model of lipopolysaccharide (LPS)-stimulated
murine macrophages and produced an increase in HO-1 expression and haem oxygenase
activity; this effect was completely prevented by the thiol donor N-acetylcysteine. Never-
theless, a more recent and detailed study showed that both CORM-2 and iCORM-2 (the
CO-depleted form) induced significant cellular toxicity evident as decreased cell viability,
abnormal cell cytology, increased apoptosis and necrosis, cell cycle arrest and reduced
mitochondrial enzyme activity. These results [67] show that the ruthenium-based CORM
by-product, iCORM-2, is itself cytotoxic and suggest that the accumulation of iCORM-2
would limit clinical applications of the ruthenium-based CORMs. The validity of using
iCORM-2 was also dismissed by [68] who showed that it inhibited activity of recombinant
cytochrome P-450. These authors also demonstrated that both CORM-2 and CORM-3
elicited a rapid depletion of oxygen in respirometry which was detected in the medium,
even when no cells were present [68]. Thus, several recent studies cast doubt on the
proposal that CORM-2 acts solely as a CO releaser.
We note also that the chemical nature of the CO-depleted ‘iCORM-2’ complexes
advocated in some studies is obscure, and so we avoided using it in this study. The structure
and ligands are unknown. It is possible that more than CO is lost as the crystal structure
of the related CORM-3 with lysozyme shows loss of two CO molecules, but attempts to
investigate whether iCORM is a mixture of interconverting compounds failed (B. Mann,
personal communication). Experimental preparations of CO-depleted CORM-2 appear
heterogeneous and to use such preparations would have produced greater uncertainty.
The fate of CORM-2 in vivo is uncertain. Virtually nothing is known of the chemi-
cal forms in which Ru exists in vivo, except for extensive knowledge of the cytological
stain Ruthenium Red, Ru polypyridyl complexes and anticancer Ru-containing molecules
(reviewed in [24]), all of which are chemically unrelated to CORM-2. Based on their mech-
anism of action, various possibilities may be considered as follows. (i) Structural: The
Ru ion(s) have a structural role, i.e., the Ru provides shape to the active compound via a
coordination sphere of ligands. These complexes are inert and biologically stable, the Ru
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interacting with the target only via noncovalent interactions. (ii) Carrier: The Ru ion(s)
simply function as carriers for the active drug, most commonly an organic compound.
(iii) Functional: The Ru ion(s) have a functional role, i.e., the antimicrobial activity of the
compound is mediated by the Ru ion directly coordinating to biological targets. These are
relatively biologically unstable compounds, often prodrugs, which contain labile ligands.
(iv) Photoactivated: The Ru compound is active only upon illumination where it can act as
a photosensitizer. We consider class (iii) to be the most likely mechanism here [24].
However, in the context of CORM-2 interactions in vivo, Cys and GSH are of special
interest as CORM-2-reactive molecules, and the liver is regarded as the site of cysteine
homeostasis. Much of the sulphur amino acid load reaching the liver is incorporated into
GSH and then exported for use by other tissues [69], where it is broken down by tissues
that express γ-glutamyl transpeptidase. The release of Cys in the peripheral circulation
results in tissues being exposed to relatively high concentrations of cysteine. Hepatic Cys
levels in rats are between 0.02–0.04 µmol g−1, and for GSH 1.65–4.36 µmol g−1, dependent
on diet [70]. Cys and cystine constitute the predominant low-molecular-weight thiol–
disulphide pool in human plasma [71]. However, GSH is more likely to remain reduced in
an oxidative environment than Cys and is maintained in tissues at millimolar concentration
with a relatively reduced redox state [72], indicating that the Cys/CySS and GSH/GSSG
pool are not in equilibrium [71]. Such high levels of thiols in the body suggest limited access
of administered CORM-2 to tissues. Thus, our results suggest that the biological effects of
CORM-2 in vivo are due to ruthenium rather than CO release. It is, however, important
to note that the results reported here are obtained from E. coli, and require experimental
confirmation in mammalian systems.
Whether or not long-term toxicity is confirmed, the present data raise the question: is
CORM-2 effective as a CO releaser in vivo? The levels of CORM-2 accumulating in liver
are unknown and would be of dubious relevance as CO is likely to have been released
before access to the liver. Nevertheless, Seixas et al. [22] measured the ability of CORM-3
to deliver CO specifically to organs and tissues and compared it with CO inhalation by
mice. CO accumulated mainly in the liver, kidney and spleen, where CO levels increased
by a factor of ca. 3, while that in the heart increased by a factor of 2; the lungs and brain
remained essentially at baseline values.
5. Conclusions
To summarise, we demonstrated that the amount of CO released from CORM-2 is
inadequate to explain its toxicity. Rather, CORM-2 reacts with thiol-containing compounds,
of which cysteine (free and in proteins) and reduced glutathione are key players in its
physiological effects. These reactions dramatically reduce the toxic effects of CORM-2.
While the biological chemistry of Ru complexes is far from completely understood [24], the
toxic effects of Ru CORMs on bacterial and (by extrapolation) mammalian cells can now be
largely attributed to the chemical reactivity of Ru, and not CO.
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